Identification of vaccine candidate antigens of Staphylococcus pseudintermedius by whole proteome characterization

Natacha Couto1, Joana Martins2, Ana Mafalda Lourenço3

  • 1Antibiotic Resistance Laboratory, CIISA, Faculdade de Medicina Veterinária, Universidade de Lisboa (FMV-UL), Av. da Universidade Técnica, 1300-477 Lisbon, Portugal; Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal.

Journal of Proteomics
|January 2, 2016
PubMed

Insights

New research identifies potential vaccine targets against methicillin-resistant Staphylococcus pseudintermedius (MRSP) infections in dogs. This study characterized S. pseudintermedius proteins to find antigens for novel vaccine development against this resistant bacteria.

Area of Science:

  • Veterinary Microbiology
  • Bacterial Pathogenesis
  • Vaccine Development

Background:

  • Methicillin-resistant Staphylococcus pseudintermedius (MRSP) poses a significant challenge in treating canine bacterial infections.
  • The emergence of antibiotic resistance necessitates the development of alternative therapeutic strategies, such as vaccines.

Purpose of the Study:

  • To identify potential vaccine candidate antigens from the proteome of S. pseudintermedius.
  • To characterize immunogenic proteins for the development of novel control strategies against MRSP infections.

Main Methods:

  • Proteomic analysis using 2-DE MALDI-TOF/TOF to characterize the S. pseudintermedius proteome.
  • SERological Proteome Analysis (SERPA) and Western blot with canine sera to identify immunogenic surface proteins.
  • In-gel digestion and protein identification of selected antigenic spots.

Main Results:

  • 361 unique proteins, including 39 surface proteins, were identified in S. pseudintermedius.
  • Four antigenic proteins were identified as promising candidates for vaccine development based on immunogenicity in infected dogs.
  • No specific preventative antibodies were found in dogs with non-infected atopic dermatitis.

Conclusions:

  • The SERPA approach successfully identified novel candidate antigens for MRSP vaccine development.
  • Targeting these identified proteins may lead to effective vaccines against S. pseudintermedius infections in dogs.
  • Further research is warranted to validate these candidates for therapeutic use.

Related Concept Videos